References
1 AJ Moss, WJ Hall, DS Cannom, JP Daubert, SL Higgins, H Klein, et al., Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 335(26) (1996) 1933-1940.
2 SH Hohnloser, KH Kuck, P Dorian, RS Roberts, JR Hampton, R Hatala, et al., Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351(24) (2004) 2481-2488.
3 SL Rosenkaimer, I El-Battrawy, TC Dreher, S Gerhards, S Roger, J Kuschyk, et al., The wearable cardioverter-defibrillator: Experience in 153 patients and a long-term follow-up. J Clin Med 9(3) (2020).
4 M Winther-Jensen, J Kjaergaard, JF Lassen, L Kober, C Torp-Pedersen, SM Hansen, et al., Implantable cardioverter defibrillator and survival after out-of-hospital cardiac arrest due to acute myocardial infarction in denmark in the years 2001-2012, a nationwide study. Eur Heart J Acute Cardiovasc Care 6(2) (2017) 144-154.
5 AM Feldman, H Klein, P Tchou, S Murali, WJ Hall, D Mancini, et al., Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: Results of the wearit/biroad. Pacing Clin Electrophysiol 27(1) (2004) 4-9.
6 B Kovacs, S Reek, AM Saguner, N Krasniqi, U Eriksson and F Duru, Outcomes during and after the use of the wearable cardioverter-defibrillator in a tertiary-care and a regional hospital in switzerland. Swiss Med Wkly 149((2019) w20136.
7 JP Piccini, Sr., LA Allen, PJ Kudenchuk, RL Page, MR Patel, MP Turakhia, et al., Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: A science advisory from the american heart association. Circulation 133(17) (2016) 1715-1727.
8 JE Olgin, MJ Pletcher, E Vittinghoff, J Wranicz, R Malik, DP Morin, et al., Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med 379(13) (2018) 1205-1215.
9 JW Erath, B Assmus, A Burch, D Bondermann, AM Russo and V Kutyifa, Sustained ventricular tachyarrhythmia termination in a large cohort of women using wearable cardioverter-defibrillators. JACC Clin Electrophysiol 6(9) (2020) 1187-1188.
10 I Goldenberg, JW Erath, AM Russo, AE Burch, B Assmus, D Bonderman, et al., Sex differences in arrhythmic burden with the wearable cardioverter-defibrillator. Heart Rhythm 18(3) (2021) 404-410.
11 P Ponikowski, AA Voors, SD Anker, H Bueno, JGF Cleland, AJS Coats, et al., 2016 esc guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (esc)developed with the special contribution of the heart failure association (hfa) of the esc. Eur Heart J 37(27) (2016) 2129-2200.
12 P Riis, Perspectives on the fifth revision of the declaration of helsinki. JAMA 284(23) (2000) 3045-3046.
13 HU Klein, I Goldenberg and AJ Moss, Risk stratification for implantable cardioverter defibrillator therapy: The role of the wearable cardioverter-defibrillator. Eur Heart J 34(29) (2013) 2230-2242.
14 S Reek, H Burri, PR Roberts, C Perings, AE Epstein, HU Klein, et al., The wearable cardioverter-defibrillator: Current technology and evolving indications. Europace 19(3) (2017) 335-345.
15 FM Kusumoto, KR Bailey, AS Chaouki, AJ Deshmukh, S Gautam, RJ Kim, et al., Systematic review for the 2017 aha/acc/hrs guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society. Circulation 138(13) (2018) e392-e414.
16 P Ponikowski, AA Voors, SD Anker, H Bueno, JG Cleland, AJ Coats, et al., 2016 esc guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (esc). Developed with the special contribution of the heart failure association (hfa) of the esc. Eur J Heart Fail 18(8) (2016) 891-975.
17 G Amit, M Suleiman, Y Konstantino, D Luria, M Kazatsker, I Chetboun, et al., Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: Lessons from the nationwide israeli-icd registry. Europace 16(8) (2014) 1175-1180.
18 AA Merz and S Cheng, Sex differences in cardiovascular ageing. Heart 102(11) (2016) 825-831.
19 NK Wassnig, M Gunther, S Quick, C Pfluecke, F Rottstadt, SJ Szymkiewicz, et al., Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circulation 134(9) (2016) 635-643.
20 JE Olgin, BK Lee, E Vittinghoff, DP Morin, S Zweibel, E Rashba, et al., Impact of wearable cardioverter-defibrillator compliance on outcomes in the vest trial: As-treated and per-protocol analyses. J Cardiovasc Electrophysiol 31(5) (2020) 1009-1018.
21 R Garcia, N Combes, P Defaye, K Narayanan, L Guedon-Moreau, S Boveda, et al., Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: The wearit-france cohort study. Europace 23(1) (2021) 73-81.
22 A Auricchio, H Klein, CJ Geller, S Reek, MS Heilman and SJ Szymkiewicz, Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation. Am J Cardiol 81(10) (1998) 1253-1256.
23 MK Chung, SJ Szymkiewicz, M Shao, E Zishiri, MJ Niebauer, BD Lindsay, et al., Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. J Am Coll Cardiol 56(3) (2010) 194-203.
24 ET Zishiri, S Williams, EM Cronin, EH Blackstone, SG Ellis, EE Roselli, et al., Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol 6(1) (2013) 117-128.